Daily CSR https://www.dailycsr.com/ 2026-09-09T19:50:45+02:00 Webzine Maker https://www.dailycsr.com/favicon.ico AsymBio Expands Biologics CDMO with New Shanghai R&D Center 2026-07-27T15:54:00+02:00 https://www.dailycsr.com/AsymBio-Expands-Biologics-CDMO-with-New-Shanghai-R-D-Center_a5993.html https://www.dailycsr.com/photo/art/imagette/97489427-67887309.jpg 2026-07-27T15:52:00+02:00 Debashish Mukherjee AsymBio Expands Biologics CDMO with New Shanghai R&D Center

AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) under the Asymchem Group (stock codes: 002821.SZ / 6821.HK), has announced the groundbreaking of a new research and development facility at its Fengxian campus in Shanghai. This expansion represents a major milestone in enhancing the company's biologics CDMO capabilities while further establishing the Fengxian site as a key center for research, development, and manufacturing.

Construction commenced in May 2026, with completion and operational launch planned for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land and offer nearly 20,000 square meters of total floor space. Designed in accordance with green and low-carbon building principles, the facility will house capabilities for cell line development, upstream and downstream process development, conjugation process development, drug product development, and advanced analytical services.

Situated alongside AsymBio's existing clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs) at the Fengxian campus, the new R&D center will serve as a dedicated innovation hub. Its close integration with manufacturing operations is expected to improve technology transfer, facilitate efficient scale-up, and accelerate the transition from development to commercial production.

The facility will also host the AccPCC (Accelerated PCC Platform), an integrated research and development framework designed to reduce the time required to advance drug candidates from lead identification to preclinical candidate (PCC) selection. Leveraging AI-enabled, end-to-end workflows, the platform brings together early-stage research, Chemistry, Manufacturing and Controls (CMC), nonclinical evaluation, and early clinical translation. It offers comprehensive support in lead optimization, developability assessment, and customized early-stage CMC strategies for biotechnology companies worldwide.

Commenting on the initiative, AsymBio CEO Rui Yang emphasized that successful biologics development depends on early collaboration, integrated scientific and CMC decision-making, and consideration of manufacturability from the beginning of a project. By utilizing the combined R&D expertise available across the Asymchem Group, the AccPCC platform aims to enhance development efficiency, accelerate preclinical candidate selection, and shorten the journey from scientific discovery to clinical application.

The new Fengxian R&D building is expected to strengthen collaboration between research, process scale-up, and manufacturing, enabling clients to minimize development bottlenecks and manage complex biologics programs with greater efficiency and confidence.


]]> CMI and Tetra Pak Launch Expanded Dairy Facility in New York 2025-07-07T15:18:00+02:00 https://www.dailycsr.com/CMI-and-Tetra-Pak-Launch-Expanded-Dairy-Facility-in-New-York_a4915.html https://www.dailycsr.com/photo/art/imagette/89768554-63421131.jpg 2025-07-07T15:16:00+02:00 Debashish Mukherjee CMI and Tetra Pak Launch Expanded Dairy Facility in New York
Cayuga Milk Ingredients (CMI), in partnership with Tetra Pak—an industry leader in food processing and packaging—has officially launched its expanded facility in Auburn, Cayuga County. This milestone marks the completion of the first phase of a significant two-part, multimillion-dollar investment in New York state.

Coinciding with National Dairy Month in June, the ribbon-cutting ceremony welcomed local and state officials, along with representatives from major dairy organizations such as the New York Farm Bureau, New York Animal Agriculture Coalition, Northeast Agribusiness and Feed Alliance, and Northeast Dairy Producers Association.

CMI stands out in the global food industry, processing approximately 1.5 billion pounds of milk annually from 65,000 acres of rich farmland. The business is collectively owned and operated by 22 farm families managing 32 farms across the Finger Lakes region. Their product offerings include a range of dairy-based ingredients like milk and protein powders, as well as fluid milk. With the addition of a new consumer-grade dairy production facility, CMI is reinforcing its role as a fully integrated, premium contract manufacturer for high-value, innovative dairy items—focused on enhancing nutritional quality while maintaining environmental responsibility.

“Shelf-stable technology is transforming what’s possible in the food and beverage space,” said Mat Rutz, Vice President of Contract Manufacturing at Tetra Pak for the U.S. and Canada. “Collaborating with CMI to broaden their capabilities through our advanced packaging and processing solutions is an exciting step forward. We're committed to sustainable industry growth and proud to be part of this evolution.”

Tetra Pak and CMI are united in their environmental mission, emphasizing sustainability across the production and supply chain. This facility expansion—supported by state-level incentives—further promotes the use of shelf-stable packaging that not only cuts costs and improves efficiency but also reduces food waste and the carbon footprint tied to shipping and storage.
The project has already created over 350 construction-related jobs, with an additional 150 permanent positions expected once the plant becomes fully operational in fall 2025—a major boost to workforce development in New York’s agricultural sector.

“This new consumer products facility represents a bold step forward, where innovation and sustainable agriculture converge to redefine food production,” said Brian Linney, CMI’s CEO. “As a cornerstone of New York’s dairy economy, we’re proud to deepen our local investment with a vertically integrated facility that will deliver both community benefits and broader economic returns for the state.”

Facility Overview
  • The expansion adds 235,000 square feet of advanced production space to CMI’s operations
  • The initiative follows a two-phase development plan:
    • Phase One: Expansion of the Eagle Drive location, including the integration of UHT/aseptic low-acid packaging lines and state-of-the-art processing systems
    • Phase Two: Installation of additional equipment and the extension of the facility’s wastewater treatment capabilities
  • The project highlights innovation through upgraded technologies, facility enhancements, and job creation initiatives aimed at developing the local workforce

]]>